Comparison
Two copper tripeptides with a single amino acid difference between them, yet distinct receptor affinities, biological activity profiles, and research depth. Both are used in skin and hair applications, but for different reasons.
Quick Answer
GHK-Cu (Glycine-Histidine-Lysine copper) is the more extensively researched copper peptide with broad effects across skin repair, wound healing, anti-inflammatory signalling, and hair follicle stimulation. AHK-Cu (Alanine-Histidine-Lysine copper) is a structural analogue differing only in the first amino acid, with higher copper binding affinity and more targeted activity in dermal papilla cells and hair follicles. GHK-Cu is the better-studied compound with wider applications. AHK-Cu is more specialised for hair and may offer advantages in follicular applications, but has significantly less research behind it.
| Attribute | GHK-Cu | AHK-Cu |
|---|---|---|
| Full name | Glycine-Histidine-Lysine copper complex | Alanine-Histidine-Lysine copper complex |
| INCI name | Copper Tripeptide-1 | Copper Tripeptide-3 |
| First described | 1973, Loren Pickart; isolated from human plasma | Synthetic analogue; foundational study published 2007 (Pyo et al.) |
| Structure | Tripeptide: Gly-His-Lys chelated to Cu(II) | Tripeptide: Ala-His-Lys chelated to Cu(II); glycine replaced by alanine |
| Copper binding affinity | High; well-characterised Cu(II) coordination via histidine imidazole | Higher than GHK-Cu; alanine substitution enhances Cu(II) chelation stability |
| Primary research focus | Broad: skin repair, wound healing, anti-aging, hair, anti-inflammatory, gene regulation | Targeted: dermal papilla cell proliferation, hair follicle stimulation, scalp angiogenesis |
| Skin evidence | Strong; multiple in vitro, animal, and human studies on collagen, elastin, and wrinkle reduction | Limited; some fibroblast activation data, but far less studied than GHK-Cu for skin |
| Hair evidence | Moderate; follicle enlargement, follicle proliferation, increased hair shaft diameter documented | Targeted; strongest available evidence specifically for dermal papilla cell survival and VEGF induction |
| Wound healing evidence | Strong; accelerates re-epithelialisation, angiogenesis, and remodelling in multiple models | Not a primary research focus; limited wound healing data |
| Anti-inflammatory evidence | Well-documented; downregulates TNF-alpha, IL-6, NF-kB; upregulates antioxidant enzymes | Anti-apoptotic data available (caspase-3 and PARP reduction); direct anti-inflammatory data limited |
| Research volume | Extensive; 50+ published studies over five decades | Limited; primarily the 2007 Pyo et al. foundational study and a small number of follow-up publications |
| Topical concentration (typical) | 0.01% to 0.1% in serums and formulations | 0.001% to 0.01% in hair and skin formulations |
GHK-Cu and AHK-Cu are both tripeptides chelated to a copper(II) ion, making them members of the copper peptide class. Their structural relationship is close: the only difference between them is the substitution of glycine (Gly) in the first position of GHK-Cu with alanine (Ala) in AHK-Cu. Despite this single amino acid change, the two compounds have meaningfully different biological profiles.
GHK-Cu was discovered in 1973 by Loren Pickart, who isolated it from human plasma while investigating why older liver tissue functioned less efficiently in the presence of young plasma. The active component turned out to be a copper-binding tripeptide: Glycine-Histidine-Lysine complexed with Cu(II). This discovery initiated decades of research that established GHK-Cu as one of the most multi-functional naturally occurring peptides identified in human biology.
AHK-Cu is a synthetic analogue developed specifically to investigate whether the glycine-to-alanine substitution would alter copper binding characteristics and biological activity. The alanine substitution increases the stability of the copper(II) chelate complex, resulting in tighter copper coordination and different tissue-level activity. AHK-Cu is classified under the INCI system as Copper Tripeptide-3, distinct from GHK-Cu (Copper Tripeptide-1). The foundational study characterising AHK-Cu's biological activity was published in 2007 by Pyo and colleagues, and the research base for AHK-Cu remains substantially smaller than for GHK-Cu.
Both peptides are used in topical cosmetic and research formulations. Neither is approved as a pharmaceutical drug. GHK-Cu is more widely available and has a substantially broader evidence base. AHK-Cu is produced in smaller quantities and is used primarily in formulations targeting hair follicle biology.
GHK-Cu acts through multiple converging pathways. Its most characterised effect is stimulation of fibroblast activity: GHK-Cu upregulates synthesis of collagen (types I, II, and III), elastin, and glycosaminoglycans, the core components of dermal extracellular matrix. This drives improvements in skin density, elasticity, and surface texture in both in vitro fibroblast models and human skin studies.
Angiogenesis is a second well-documented pathway: GHK-Cu stimulates VEGF and FGF expression, promoting new blood vessel formation in wound beds and in follicle-adjacent tissue. This vascular effect is relevant to both wound healing and hair follicle support, where adequate microcirculation is required to sustain the anabolic demands of the hair growth cycle.
Anti-inflammatory and antioxidant activity are well-characterised: GHK-Cu downregulates TNF-alpha, IL-6, and NF-kB signalling in inflammatory models, and upregulates superoxide dismutase (SOD) and catalase, the primary enzymatic antioxidant defences. These effects are relevant to chronic inflammatory skin conditions and to the oxidative environment that accompanies UV damage and skin aging.
GHK-Cu's most distinctive and unusual property is its scope of gene regulation. Research by Pickart and colleagues using microarray analysis identified that GHK-Cu modulates the expression of more than 4,000 human genes, with a consistent pattern of upregulating tissue repair, anti-inflammatory, and anti-apoptotic pathways while downregulating inflammatory and oncogenic signalling. This places GHK-Cu in a rare category of small peptides with demonstrably broad gene-regulatory activity, though the mechanistic basis of this broad effect is not fully characterised.
For hair specifically, GHK-Cu has been shown to stimulate hair follicle proliferation, increase follicle size, and extend the anagen (growth) phase. These effects appear to be mediated partly through VEGF-driven microvascular support and partly through direct activation of follicular keratinocytes and dermal papilla cells.
Neuroprotective effects have been reported in preclinical models, including BDNF upregulation and protection against oxidative neuronal damage, though this research is less extensive than the skin and wound healing data.
AHK-Cu's characterised mechanism is more targeted than GHK-Cu's, concentrated on dermal papilla cell biology. Dermal papilla (DP) cells are specialised fibroblast-like cells at the base of each hair follicle that act as master regulators of the hair growth cycle. The inductive signalling from DP cells drives follicular keratinocyte proliferation and determines anagen initiation, anagen duration, and follicle size. Compounds that specifically support DP cell survival and proliferation therefore have a rational basis for hair growth support.
The 2007 Pyo et al. study, the foundational characterisation of AHK-Cu, demonstrated direct stimulation of DP cell proliferation in vitro and documented two specific anti-apoptotic effects: reduction of caspase-3 activity by 42.7% and reduction of PARP cleavage by 77.5% in DP cells undergoing hydrogen-peroxide-induced stress. These findings indicate that AHK-Cu actively shifts the apoptosis-survival balance in DP cells toward survival, which would be expected to prolong the productive lifespan of active follicles.
AHK-Cu has also been shown to induce VEGF expression in DP cells, contributing to angiogenesis specifically within the scalp microvascular bed that supplies follicles. This is analogous to GHK-Cu's VEGF effect but appears to be more follicle-focused rather than broadly angiogenic across different tissue types.
AHK-Cu also modulates the Bcl-2 / Bax ratio in DP cells, shifting the balance toward anti-apoptotic Bcl-2 expression. This mechanism complements the caspase-3 and PARP findings: AHK-Cu appears to engage the intrinsic apoptosis pathway at multiple control points to protect DP cell populations under stress conditions that would otherwise trigger follicle miniaturisation or loss.
Extracellular matrix remodelling effects have been reported for AHK-Cu via fibroblast activation, with some evidence for collagen and elastin synthesis stimulation. However, these data are less extensive than GHK-Cu's ECM evidence base, and the primary documented application of AHK-Cu remains follicular rather than general skin repair.
The narrower activity profile of AHK-Cu compared to GHK-Cu is a direct consequence of its structural difference. The glycine-to-alanine substitution changes the steric and electronic properties of the first amino acid position, which affects how the copper complex interacts with cell surface receptors and signalling molecules in different tissue types. GHK-Cu's broader activity may reflect glycine's role in receptor interactions that AHK-Cu does not replicate.
GHK-Cu has been studied since 1973 across in vitro models, animal studies, and human clinical evaluations. The evidence base includes more than 50 published studies covering collagen synthesis, skin elasticity, wound healing, hair follicle biology, anti-inflammatory signalling, antioxidant defence, and gene regulation. Human skin studies have confirmed improvements in skin density, elasticity, and surface texture with topical GHK-Cu at concentrations of 0.01% to 0.1%. The safety profile is well-characterised at cosmetic use concentrations.
The breadth of GHK-Cu's research base is itself a distinguishing feature. No other copper peptide has been studied across as many biological systems or over as long a timeframe. The gene regulation data, in particular, representing modulation of 4,000+ genes, goes beyond what most single peptides have been documented to do, and positions GHK-Cu as a compound with plausible systemic effects at the molecular level, not just localised tissue repair activity.
AHK-Cu's evidence base is substantially smaller. The primary published study characterising its biological activity is the 2007 Pyo et al. paper, which established the DP cell proliferation and anti-apoptotic findings. A small number of follow-up publications have investigated AHK-Cu's skin and hair effects, but the total published literature remains thin compared to GHK-Cu.
The available data for AHK-Cu on its primary target, dermal papilla cells, is internally consistent and mechanistically coherent. The anti-apoptotic findings (caspase-3 reduction, PARP cleavage reduction, Bcl-2/Bax modulation) represent convergent evidence from multiple assays pointing to the same conclusion: AHK-Cu protects DP cells from apoptotic stress. This is a credible mechanistic foundation for hair growth support, even if the clinical human evidence is not yet at the level available for GHK-Cu.
The honest summary: AHK-Cu shows real biological activity in its primary research target (DP cells), but the evidence base is too limited to draw strong conclusions about clinical efficacy, optimal concentration, or long-term safety in human use. Researchers and formulators working with AHK-Cu are extrapolating from a small evidence base, which is worth stating clearly.
For general skin health, anti-aging, wound healing, broad tissue repair, or anti-inflammatory skin applications, GHK-Cu is the clear choice. The evidence base is substantially stronger, the safety profile is well-established at cosmetic concentrations, and the compound is more widely available and lower in cost due to longer production history and wider commercial adoption.
GHK-Cu is also the better-evidenced choice for hair applications in the absence of specific reasons to prefer AHK-Cu, given that GHK-Cu's hair follicle stimulation effects are documented across multiple independent study groups over a longer research history.
For formulations specifically targeting hair follicle biology and dermal papilla cell survival, AHK-Cu may offer advantages based on its mechanism. The DP-cell-targeted anti-apoptotic activity documented in the Pyo et al. study is a more direct intervention point for follicle preservation than GHK-Cu's broader angiogenic and proliferative effects. If the primary objective is follicle rescue in the context of androgenetic alopecia or other follicle miniaturisation processes, AHK-Cu's targeted mechanism is mechanistically appropriate, despite the smaller evidence base.
Combining both compounds is commonly done in topical formulations and is mechanistically rational. There is no known antagonism between GHK-Cu and AHK-Cu. Their mechanisms are complementary: GHK-Cu provides broad repair, angiogenesis, anti-inflammatory, and antioxidant activity across the full dermal and follicular environment, while AHK-Cu adds targeted dermal papilla cell protection and VEGF induction focused on the follicular niche.
In research context formulations, typical concentrations when combining are: GHK-Cu at 0.01% to 0.1% and AHK-Cu at 0.001% to 0.01%. The lower typical concentration for AHK-Cu reflects both its higher potency in DP cell models and the practical reality that it is more expensive and less abundantly produced than GHK-Cu.
Cost is a practical consideration: GHK-Cu is considerably more affordable and accessible than AHK-Cu, which limits AHK-Cu's use to specialist formulations where its targeted follicular mechanism justifies the additional cost. Many commercial hair care formulations that list both copper peptides are using GHK-Cu as the primary active and AHK-Cu as a complementary follicular agent at a lower concentration.
GHK-Cu (Glycine-Histidine-Lysine copper, INCI: Copper Tripeptide-1) and AHK-Cu (Alanine-Histidine-Lysine copper, INCI: Copper Tripeptide-3) are both tripeptides chelated to a copper ion, differing only in the first amino acid. Glycine in GHK-Cu is replaced by alanine in AHK-Cu. This substitution increases AHK-Cu's copper binding affinity but narrows its biological activity to more targeted follicular effects. GHK-Cu has broad documented activity across skin repair, wound healing, anti-inflammatory signalling, and hair follicle stimulation, backed by 50+ studies over five decades. AHK-Cu is primarily characterised for dermal papilla cell protection and hair follicle stimulation, with a much smaller research base.
Both have documented activity relevant to hair growth, through different mechanisms. GHK-Cu stimulates follicle proliferation, increases follicle size, and extends the anagen phase via angiogenesis and direct follicular activation, with a stronger overall evidence base. AHK-Cu targets dermal papilla cells specifically, protecting them from apoptosis via caspase-3 and PARP reduction, and inducing VEGF for scalp microcirculation. For general hair health and anti-aging applications, GHK-Cu's broader evidence base makes it the default choice. For specifically addressing follicle miniaturisation and DP cell preservation, AHK-Cu has a mechanistically targeted rationale. Many formulations combine both.
Yes. There is no known antagonism between GHK-Cu and AHK-Cu, and their mechanisms are complementary. GHK-Cu provides broad repair and anti-inflammatory activity across the full dermal environment, while AHK-Cu adds targeted dermal papilla cell protection and follicular VEGF induction. Combining them in topical formulations is commonly done. Typical research-context concentrations when combining: GHK-Cu at 0.01% to 0.1% and AHK-Cu at 0.001% to 0.01%.
The available evidence does not support a conclusion that AHK-Cu is categorically more effective than GHK-Cu for hair. AHK-Cu shows stronger targeted activity specifically in dermal papilla cell models, particularly the anti-apoptotic data from the Pyo et al. study. However, GHK-Cu has been studied for hair follicle effects across more research groups over a longer period, and its broader angiogenic and repair activity provides a wider biological platform for follicle support. The honest answer is that neither compound has sufficient controlled human clinical trial data to make confident comparative efficacy claims. AHK-Cu's mechanism is targeted and credible for DP cell preservation specifically. GHK-Cu's mechanism is broader and better evidenced for hair effects overall.
GHK-Cu has substantially more research. It was first described in 1973 and has accumulated more than 50 published studies across skin, wound healing, hair follicle, anti-inflammatory, antioxidant, and gene regulation domains. AHK-Cu's primary characterisation comes from the 2007 Pyo et al. study, with a small number of follow-up publications. For researchers evaluating these compounds, the GHK-Cu literature provides a much deeper foundation for mechanistic interpretation and safety assessment.
AHK-Cu stands for Alanine-Histidine-Lysine copper complex. The three letters AHK refer to the three amino acids in the tripeptide sequence: Alanine (A), Histidine (H), and Lysine (K), using standard single-letter amino acid notation. Cu is the chemical symbol for copper. The full INCI name is Copper Tripeptide-3. It is a synthetic analogue of GHK-Cu (Glycine-Histidine-Lysine copper, Copper Tripeptide-1), with alanine replacing glycine in the first position of the sequence.
Related Comparisons